Universität zu Köln

Gouni-Berthold, Ioanna, Schaper, Frank, Schatz, Ulrike, Tabbert-Zitzler, Anja, Fraass, Uwe, Sauer, Sarah and Ray, Kausik K. (2022). Low-density lipoprotein cholesterol goal attainment in Germany: Results from the DA VINCI study. Atheroscler. Plus, 50. S. 10 - 17. AMSTERDAM: ELSEVIER. ISSN 2667-0895

Full text not available from this repository.

Abstract

Background and aims: Cardiovascular mortality is high in Germany. For patients with high or very high cardiovascular risk, the European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines recommend intensive lipid lowering therapy (LLT). This study aimed to assess dyslipidaemia management and achievement of the ESC/EAS guideline-recommended low-density lipoprotein cholesterol (LDL-C) goals. Methods: This European 18-country, cross-sectional, observational DA VINCI study (EUPAS22075) collected data during a single visit between June 2017 and November 2018 and included LLT in the preceding 12 months and the patients' most recent LDL-C measurement. Achievement of the risk-based 2016 and 2019 ESC/EAS LDL-C goals while receiving stabilized LLT was assessed. Data from the German cohort are presented here. Results: Seven German sites enrolled a total of 421 primary and secondary prevention patients, 327 were receiving stabilized LLT at the time of LDL-C measurement, i.e. statin monotherapy of high (16%; n = 53), moderate (49%; n = 160) or low (7%; n = 24) intensity, ezetimibe combination (18%; n = 58), proprotein convertase subtilisin/kexin type 9 antibody combination (3%; n = 9), and other LLT (7%; n = 23). The 2016 and 2019 risk-based LDL-C goals were attained by 46% (n = 149) and 28% (n = 92) of patients, respectively. Conclusions: There is a large gap between ESC/EAS recommendations and LDL-C goal achievement in routine clinical practice in high and very high-risk patients in Germany. Low-to-moderate-intensity statin monotherapy was the most frequently used LLT; use of high-intensity statins and combination therapy was limited. In addition to optimizing statin intensity, combination with non-statin LLT may be needed in most of these patients. (c) 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Gouni-Berthold, Ioanna UNSPECIFIED UNSPECIFIED UNSPECIFIED Schaper, Frank UNSPECIFIED UNSPECIFIED UNSPECIFIED Schatz, Ulrike UNSPECIFIED UNSPECIFIED UNSPECIFIED Tabbert-Zitzler, Anja UNSPECIFIED UNSPECIFIED UNSPECIFIED Fraass, Uwe UNSPECIFIED UNSPECIFIED UNSPECIFIED Sauer, Sarah UNSPECIFIED UNSPECIFIED UNSPECIFIED Ray, Kausik K. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-684772
DOI:	10.1016/j.athplu.2022.07.024
Journal or Publication Title:	Atheroscler. Plus
Volume:	50
Page Range:	S. 10 - 17
Date:	2022
Publisher:	ELSEVIER
Place of Publication:	AMSTERDAM
ISSN:	2667-0895
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CORONARY-HEART-DISEASE; HIGH CARDIOVASCULAR RISK; LIPID-MODIFYING THERAPY; CLINICAL-PRACTICE; DIABETES-MELLITUS; LOWERING THERAPY; LDL-CHOLESTEROL; MANAGEMENT; DYSLIPIDEMIA; GUIDELINES Multiple languages Peripheral Vascular Disease Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/68477